BioStock: Cereno Scientific discusses phase IIa results for CS1

The trial was made with the company’s lead candidate, CS1, in the rare cardiovascular disease Pulmonary Arterial Hypertension. See Sten R Sörensen, CEO, announce the results and their impact on Cereno Scientific.

See the interview at biostock.se:

https://www.biostock.se/en/2024/10/cereno-scientific-discusses-phase-iia-results-for-cs1/

This is a press release from BioStock - Connecting Innovation & Capital.